US Expands MFN Drug Pricing to 26 Manufacturers

MFN drug pricing in the United States now spans 26 pharmaceutical manufacturers, after the White House announced agreements with nine additional companies on August 31, 2026. The deals extend most-favored-nation prices, benchmarked to the lowest prices paid by other developed nations, across 89% of the branded drug market.

The nine manufacturers are mid-sized pharmaceutical companies: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. Their agreements cut prices on medicines for a range of costly, chronic, and rare conditions, including hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin conditions, and several forms of cancer.

MFN drug pricing reaches state Medicaid programs

Every state Medicaid program in the country gains access to most-favored-nation pricing on products made by the nine companies, which the White House expects to yield billions of dollars in savings. The agreements also guarantee MFN prices on all new innovative medicines the nine manufacturers bring to market, a safeguard intended to prevent other nations from using price controls to underpay for American innovation.

Ad

Manufacturing investment and the SAPIR reserve

The nine manufacturers have committed to invest at least $19.6 billion collectively in US manufacturing in the near term. Several are also donating active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), a stockpile built to reduce reliance on foreign suppliers and keep an adequate supply on hand for emergencies.

The donations include 163 tons of levetiracetam, an anticonvulsant used to control and prevent certain seizures, from UCB; 71.4 tons of clindamycin and 6.75 tons of doxycycline, both antibiotics, from Sun Pharma; 45 metric tons of metronidazole, an antibiotic and antiprotozoal, plus 4.8 tons of amlodipine, an antihypertensive, from Teva Pharmaceuticals; and 25 kg of tacrolimus, an immunosuppressant used to prevent organ rejection after transplants, from Astellas.

Savings through TrumpRx and the $50 GLP-1 program

Patients have saved more than $700 million on medicines through TrumpRx since the portal launched in February 2026. In July 2026, senior citizens without GLP-1 coverage for obesity gained access to these treatments for $50 per month, and more than 500,000 seniors have saved a combined $216 million in the two months since. The Council of Economic Advisers estimates total savings from the MFN deals at $600 billion over the next decade.

How the program unfolded

President Trump signed an executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” on May 12, 2025. On July 31, 2025, he sent letters to 17 of the leading pharmaceutical manufacturers outlining the steps needed to bring US prices in line with the lowest price offered in other developed nations; the administration now holds MFN deals with each of them.

The first agreement, with Pfizer, was announced on September 30, 2025. On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom that will increase the net price of new prescription drugs by 25% in the UK. Nine agreements with major pharmaceutical companies followed on December 19, 2025, and TrumpRx.gov launched on February 5, 2026.

The full list of manufacturers

As of August 31, 2026, the administration holds MFN agreements with Pfizer, Astra Zeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie, Regeneron, Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.

The administration is also calling on Congress to enact the Great Healthcare Plan, a broader package aimed at lowering drug prices and insurance premiums, holding insurers accountable, and improving price transparency.

Source: White House fact sheet, August 31, 2026.